Expert Ratings for Sweetgreen

Over the past 3 months, 5 analysts have published their opinion on Sweetgreen (NYSE:SG) stock. These analysts are…

Over the past 3 months, 5 analysts have published their opinion on Sweetgreen (NYSE:SG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 2 3 0 0
Last 30D 0 0 1 0 0
1M Ago 0 0 0 0 0
2M Ago 0 1 0 0 0
3M Ago 0 1 2 0 0

These 5 analysts have an average price target of $15.6 versus the current price of Sweetgreen at $10.99, implying upside.

Below is a summary of how these 5 analysts rated Sweetgreen over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This average price target has increased by 5.76% over the past month.

Stay up to date on Sweetgreen analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

UnitedHealth’s Q1 Medical Cost Update, Prudent Outlook Eases Investor Concerns: Goldman Sachs

UnitedHealth impresses with Q1 results amid the aftermath of the Change Healthcare cyberattack and maintains strong guidance amidst business disruption costs. Goldman Sachs reaffirms Buy rating, citing favorable medical cost updates and prudent outlook, despite cyberattack-related challenges.

UNH

Read More

Macy’s Analyst Remains Bearish Following Disappointing Q4 Preannouncement: ‘Longer Term Structural Challenges’

Macy's Inc (NYSE: M) shares traded lower by 7.5% on Monday morning after the company preannounced disappointing holiday quarter sales numbers over the weekend. Unfortunately, one analyst said Monday that the difficult environment for Macy's is unlikely to improve in the first half of 2023.

AMZN